For years, the honest answer to the question "is there human clinical trial data on BPC-157?" has been: no.

That answer has changed.

A Phase 2 randomized, double-blind, placebo-controlled trial of BPC-157 for acute hamstring muscle strain repair has been registered on ClinicalTrials.gov under identifier NCT07437547. Trial name: BPC 157 for Acute Hamstring Muscle Strain Repair (BPC-HAMSTR).

This is the first randomized controlled trial of BPC-157 registered in a musculoskeletal injury context. It does not mean BPC-157 has been proven effective in humans. It means the research pipeline has formally entered the phase where that question will begin to be answered.

Here is exactly what the trial registration tells us — and what it doesn't.

What the Trial Is

Trial identifier: NCT07437547 Official title: BPC 157 for Acute Hamstring Muscle Strain Repair Phase: Phase 2 Design: Randomized, double-blind, placebo-controlled Intervention: Subcutaneous BPC-157 or matching placebo once daily for 14 days Study population: Adults with acute grade II hamstring muscle strain, confirmed by MRI Randomization: 1:1 (BPC-157 vs. placebo) Background: Standardized rehabilitation program in both arms Assessment timepoints: Days 3, 7, 14, 28, and 56, with 3-month follow-up after return-to-play Registry: ClinicalTrials.gov (U.S. National Library of Medicine)

Co-primary endpoints:

Time to return to unrestricted sport
Change in MRI-assessed injury volume at Day 14

What "Phase 2 Trial Registration" Actually Means

A registered trial is not a completed trial. Registration means:

A sponsor has submitted a protocol to ClinicalTrials.gov
The protocol has been reviewed and accepted by the National Library of Medicine
The study is authorized to begin enrollment
Results are not yet available

Phase 2 is the stage where a compound is tested in humans for the first time in a specific indication — evaluating safety, tolerability, and preliminary efficacy signals. Phase 2 results, if positive, lead to larger Phase 3 trials. Phase 3 results, if positive, form the basis of an FDA approval application.

This trial is at the beginning of that pathway, not the end. No results are available from NCT07437547 as of this writing.

Why This Matters

BPC-157 has been one of the most discussed compounds in the research peptide space for years. The mechanistic rationale — angiogenesis, fibroblast activation, growth hormone receptor upregulation in tendon tissue — is well-supported in preclinical (animal and in-vitro) research. The 2025 systematic review by Vasireddi et al. in the HSS Journal synthesized the preclinical orthopaedic sports medicine literature and confirmed the cytoprotective mechanism across tendon, ligament, muscle, and fracture repair models. The review's conclusion was explicit: "No studies report on in-human clinical safety or adverse events. The in-human safety remains unknown."

NCT07437547 begins to address that gap.

Hamstring strains are a practical and well-defined injury to study — common in running and field-based sports, with known recurrence rates and clear MRI-measurable endpoints. The choice of acute grade II hamstring strain as the study population reflects the kind of condition where BPC-157's mechanism (accelerated tissue healing, angiogenesis, fibroblast activation) would theoretically produce a measurable effect in a reasonable timeframe.

The 14-day primary endpoint for MRI-assessed injury volume change is also notable — it aligns with BPC-157's documented pharmacokinetics (sub-30-minute elimination half-life) and the expected timeline for angiogenesis-driven healing in preclinical models.

What This Trial Does Not Change — Yet

Registration of a Phase 2 trial is a significant step. It is not:

Evidence that BPC-157 works in humans
A change in BPC-157's regulatory status
An indication that BPC-157 is safe for human use (that is what the trial is designed to evaluate)
A pathway to immediate clinical compounding access

Regulatory status as of June 2026: BPC-157 left the FDA's Category 2 restricted list on April 23, 2026 when its original nominating companies withdrew their nominations. The FDA's Pharmacy Compounding Advisory Committee meets July 23-24, 2026 to formally review BPC-157 for inclusion on the 503A Bulks List — which, if approved and finalized, would create the prescription-accessible compounding pathway. Final rulemaking following PCAC recommendation is estimated to be at least 12 months beyond the meeting.

The human clinical trial and the regulatory pathway are parallel tracks. One does not depend on the other. Both represent forward movement for the compound.

The Broader Context: Why Now

The timing of this trial registration is not coincidental. The regulatory opening (April 23 Category 2 departure), the July PCAC meeting, and the growing mainstream attention to BPC-157 have all converged to create conditions where a formal human study becomes both scientifically motivated and commercially viable.

The research community has been watching BPC-157 for decades. The preclinical evidence base is unusually large for a compound with no human trial data. NCT07437547 is the natural next step — not a surprise, but a milestone.

For anyone tracking the peptide space, this trial is worth following. The co-primary endpoints (return-to-sport time and MRI injury volume at Day 14) are objective, measurable, and clinically meaningful. If the Phase 2 results are positive, it would provide the first human evidence for a mechanism that has been compelling in animal models for 30 years.

What to Watch

Trial results: ClinicalTrials.gov (NCT07437547) will post results when they become available. No projected completion date is listed at this time.

July 23-24, 2026 PCAC meeting: The advisory committee review of BPC-157 for 503A Bulks List inclusion is the regulatory parallel track. Docket FDA-2026-N-2979 is open for public comment until July 22, 2026.

PeptidesGPT AI Coach: Updated with the trial registration and current regulatory status. Ask the Coach for the current status of BPC-157 at any time.

→ Ask the Coach at PeptidesGPT.com

Sources:

ClinicalTrials.gov NCT07437547 — BPC 157 for Acute Hamstring Muscle Strain Repair (BPC-HAMSTR)
Vasireddi N et al. (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. DOI: 10.1177/15563316251355551
FDA PCAC meeting calendar — July 23-24, 2026. Docket FDA-2026-N-2979
FDA.gov — Category 2 nomination withdrawal, effective April 23, 2026

PeptidesGPT is an educational platform. The content above discusses a registered clinical trial and the current research and regulatory status of BPC-157 for informational purposes only. It is not medical advice. BPC-157 is not FDA-approved for any indication. Always consult a licensed healthcare provider before making any protocol decisions.